It is an exciting time for those clinicians who manage patients with dyslipidemia. The field has medical therapies, novel and highly targeted mechanisms of action, new delivery methods, and safety and tolerability that suggest our therapeutic arsenal will be expanding soon and rapidly. At the AHA Scientific Sessions in New Orleans in November 2025, several very noteworthy trials were presented and warranted inclusion in the ‘Late Breaker’ sessions—a remarkable burst of new and exciting data. Our expert faculty—Drs. Brown, Taub, and Toth were there on the scene and selected the trials that they felt were most impactful. In this continuing education podcast, they discuss these new data and provide contextualization for their potential clinical impact.
Complete the pre-quiz poll to access the course episodes.
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity.
Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Alan S. Brown, MD | Consultant/Advisor: Amgen Incorporated; Arrowhead Pharmaceuticals, Inc.; Ionis Pharmaceuticals; Merck & Co., Inc.; NewAmsterdam Pharma; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc. Speaker's Bureau: Amgen Incorporated; Ionis Pharmaceuticals; Regeneron Pharmaceuticals Inc. |
| Pam R. Taub, MD | Consultant/Advisor: Amarin; Amgen Incorporated; Bayer AG; Boehringer Ingelheim; Esperion Therapeutics, Inc; Medtronic, Inc; Novartis Pharmaceuticals Corporation; Novo Nordisk |
| Peter P. Toth, MD, PhD | Consultant/Advisor: Merck & Co., Inc. Speaker's Bureau: Amgen Incorporated |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC, Chelsey Simonds and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour, including 1.0 Pharmacotherapeutic Contact Hour (Provider #P0491).
AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of Continuing Pharmacy Education Credit (UAN # JA4008190-0000-25-036-H01-P).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Amgen.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606
